NCT05442749 2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2 Terminated
Clinical Trials
7 trialsNCT03601923 2026-01-28
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04493060 2025-08-07
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Completed
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04764084 2021-02-21
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Peking University Cancer Hospital & Institute
Phase 1 Unknown